MAP3K1及LSP1基因单核苷酸多态与中国北方汉族绝经前妇女乳腺癌风险相关性

目的:探讨MAP3K1及LSP1基因单核苷酸多态与中国北方汉族绝经前妇女乳腺癌风险的关系。方法:采用多重单碱基延伸单核苷酸多态性分型技术(Snapshot)分析方法,检测280例绝经前乳腺癌患者和287例绝经前正常对照者MAP3K1基因rs889312和LSP1基因rs3817198多态性位点基因型,并比较不同基因型与乳腺癌风险的关系。结果:MAP3K1基因rs889312和LSP1基因rs3817198多态性位点基因型频率在乳腺癌和对照样本之间未存在显著差异(P=0.937、P=0.323)。Logistic回归分析结果显示,对于MAP3K1的rs889312位点,与AA携带者相比,AC携带者、CC携带者和AC+CC基因型携带者与乳腺癌的患病危险无关(OR=0.814,95%CI=0.537-1.236,P=0.335;OR=0.999,95%CI=0.627-1.594,P=0.998;OR=0.876,95%CI=0.591-1.298,P=0.509);对于LSP1的rs3817198位点,与TT携带者相比,CT携带者、CC携带者和CT+CC基因型携带者与乳腺癌的患病危险无关(OR=0.832,95%CI=0.565-1.223,P=0.349;OR=0.651,95%CI=0.108-3.936,P=0.640;OR=0.839,95%CI=0.573-1.229,P=0.369)。结论:上述两个基因MAP3K1和LSP1位点多态性与中国北方汉族绝经前妇女乳腺癌易感性之间无明显相关性。     

FGFR3基因单核苷酸多态与绝经前乳腺癌易感性的关联研究

目的 探讨FGFR3基因单核苷酸多态(SNPs)与女性绝经前乳腺癌的风险关系。方法 采用多重单碱基延伸SNP分型技术(Snapshot)检测FGFR3基因的rs2234909和rs3135848的SNP基因型在绝经前乳腺癌患者和绝经前正常女性人群中的频率,并分析不同SNP基因型与绝经前乳腺癌发病的风险关系。结果 FGFR3基因rs2234909和rs3135848的SNP基因型的频率在乳腺癌与对照组间无统计学差异(P＞0.05)。Logistic回归分析结果显示,对于rs2234909位点,相比较于TT基因型,TC和TC+CC基因型和乳腺癌的发病风险无显著相关性(OR=1.035,95% CI:0.680~1.575,P=0.874;OR=0.985,95% CI:0.638~1.521,P=0.945);对于rs3135848位点,相比较于TT基因型,TC、CC和TC+CC基因型与乳腺癌的发病风险无关(OR=1.177,95% CI:0.846~1.636,P=0.333;OR=0.948,95% CI:0.287~3.137,P=0.931;OR=1.162,95% CI:0.548~1.112,P=0.360)。rs2234909位点突变的乳腺癌患者与未突变者相比,组织学分级(显性模型:P=0.032;共显性模型:P=0.024)以及Ki67指数(显性模型:P=0.056;共显性模型:P=0.044)显著增高;rs3135848位点突变及两位点均突变与乳腺癌患者临床病理特征无显著相关性(P＞0.05)。结论 FGFR3基因的rs2234909和rs3135848两位点基因多态性与乳腺癌易感性无明显相关性;而rs2234909位点突变在绝经前乳腺癌患者中与组织学分级和Ki67指数呈正相关,可能提示预后不良。     

ATM基因多态性与乳腺癌患病风险及临床病理特征的相关性分析

目的:探讨共济失调毛细血管扩张突变基因（ataxia-telangiectasia mutated gene,ATM）单核苷酸多态性（SNP）rs189037和rs609261两个位点多态性与乳腺癌患病风险及临床病理特征的关系。方法:收集我院未接受放、化疗的乳腺癌根治标本和乳腺良性肿瘤标本。采用多重SNaPshot法检测ATM基因rs189037和rs609261两个位点多态性,分析其与乳腺癌患病风险及临床病理特征的关系。结果:ATM基因rs189037位点多态性与乳腺癌患癌风险及临床病理特征无关（GA基因型,P=0.667）;rs609261位点携带TC、CC基因型的淋巴结转移患者患癌风险高于TT基因型携带者（TC+CC显性模型,P=0.015）。ATM基因rs189037和rs609261两个位点等位基因频率和基因型分布与免疫组化指标（ER、PR、HER2、Ki-67）无相关性（rs189037位点GA+AA显性模型和rs609261位点TC+CC显性模型,ER:P=0.676、0.675;PR:P=0.758、0.573;HER2:P=0.203、0.327;Ki-67:P=0.189、0.405）。结论:ATM基因rs189037位点与乳腺癌患癌风险及临床病理特征、免疫组化指标无明显相关性。rs609261位点携带TC、CC基因型的淋巴结转移患者可能增加患病风险。     

甘肃汉族妇女XRCC1和CCNH基因多态性与乳腺癌及乳腺良性肿瘤易感性研究

目的： 研究甘肃地区汉族妇女XRCC1 rs25487、CCNH rs2234942基因多态性与乳腺癌及乳腺良性肿瘤发病的相关性。方法：选取经病理组织学确诊的乳腺癌、乳腺良性肿瘤各101例,匹配相同数量健康人作对照。使用聚合酶链式反应-限制性片段长度多态分析技术(PCR-RFLP)对XRCC1、CCNH进行基因型分析,通过Logistic回归分析不同基因型和临床病理特征与乳腺癌发病的风险性关系,通过χ2检验比较两种基因位点不同基因型的初潮年龄、发病年龄与乳腺癌和乳腺良性肿瘤的相关性。结果：Logistic回归分析发现XRCC1 rs25487位点GG基因型携带者的妇女罹患乳腺癌的危险性增加(P=0.001, OR=6.39, 95%CI： 2.18～ 18.65);临床病理免疫组化分析显示,XRCC1基因 rs25487位点携带AA/AG基因型者,在PR+与PR-乳腺癌组织间的分布差异有显著性(P=0.04,OR=0.29);携带AG/GG基因型者,在Her-2+与Her-2-乳腺癌组织间的分布差异有显著性(P=0.008, OR=0.45)。χ2检验显示,乳腺癌和乳腺良性肿瘤患者XRCC1 rs25487位点GG/AG基因型携带者的初潮年龄差异有显著性(P=0.001、0.043);乳腺癌和乳腺良性肿瘤患者CCNH rs2234942位点GG基因型携带者的初潮年龄差异有显著性(P=0.049);乳腺癌和乳腺良性肿瘤患者XRCC1 rs25487和CCNH rs2234942位点GG基因型携带者,发病年龄差异有显著性(P=0.019、0.048)。结论：XRCC1 rs25487 GG基因型将会增加乳腺癌的发病风险,XRCC1 rs25487位点携带AA/AG基因型者,在PR+时乳腺癌的发病风险下降;携带AG/GG基因型者,在Her-2+时可能降低乳腺癌的发病风险。     

2q35 rs13387042和8q24 rs13281615单核苷酸多态性与中国东北汉族绝经前妇女乳腺癌风险关系

背景与目的：乳腺癌作为中国女性最常见的恶性肿瘤,每年的新发数量和死亡数量分别占全世界的12.2%和9.6%,但与中国乳腺癌患者明显相关的基因多态位点至今尚不清楚。本研究旨在探讨2q35 rs13387042和8q24 rs13281615单核苷酸多态性与中国北方汉族绝经前妇女乳腺癌风险关系,为预防和治疗乳腺癌提供循证依据。方法：采用多重单碱基延伸单核苷酸多态性分型技术(SNaPshot)分析方法,检测了280例绝经前乳腺癌患者和287例绝经前正常对照者2q35 rs13387042和8q24 rs13281615多态性位点基因型,并比较不同基因型和等位基因与乳腺癌风险的关系。结果：2q35 rs13387042多态性位点基因型频率在乳腺癌和对照样本之间差异有统计学意义(P=0.017);8q24 rs13281615多态性位点基因型频率在乳腺癌和对照样本之间差异无统计学意义(P=0.967)。Logistic回归分析结果显示,对于2q35 rs13387042位点,与GG相比,GA和GA+AA基因型携带者显著增加乳腺癌的患病风险(OR=1.793,95%CI：1.177～2.733,P=0.007;OR=1.691,95%CI：1.122～2.550,P=0.012),而AA携带者与乳腺癌的患病风险无关(OR=0.572,95%CI：0.104～3.153,P=0.521);与G等位基因相比,A等位基因显著增加乳腺癌的患病风险(OR=1.505,95%CI：1.033～2.193,P=0.033)。对于8q24rs13281615位点,与AA相比,AG、GG和AG+GG基因型携带者与乳腺癌的患病风险无关(OR=0.992,95%CI：0.660～1.490,P=0.968;OR=1.047,95%CI：0.642～1.708,P=0.853;OR=1.007,95%CI：0.682～1.487,P=0.971);与A等位基因相比,G等位基因不增加乳腺癌患病风险(OR=1.021,95%CI：0.809～1.288,P=0.863)。结论：本实验证实2q35 rs13387042多态性位点能够增加中国北方汉族绝经前妇女乳腺癌易感风险,而8q24 rs13281615多态性位点与中国北方汉族绝经前妇女乳腺癌易感性无明显相关性。     

PALB2基因遗传多态性在早发性乳腺癌中的作用

背景与目的:PALB2基因是新近发现的乳腺痛易感基因,其多个遗传单核苷酸多态性(SNP)可能与乳腺癌发病风险有关,本研究探讨PALB2基因rs249954、rs447529及rs16940342多态性在福建早发性乳腺癌人群中的分布及其与乳腺癌发病风险的相关性.方法:对124例早发性乳腺癌患者(年龄≤35岁)和101例健康女性进行PALB2基因rs249954、rs447529及rs16940342 PCR扩增,并采用基质辅助激光解吸电离飞行时间质谱分析(MALDI-TOF-MS)法鉴定其基因型,比较各基因型分布和发病风险的关系;应用非条件Logistic回归分析计算危险度(OR)及95%CI.结果:PALB2基因rs249954、rs447529及rs16940342多态性基因型在病例组中的分布频率与对照组的分布频率均未见明显差异(P＞0.05).Logistic回归分析表明,在早发性乳腺癌人群中,以rs249954的CC基因型、rs447529 CC基因型及rs16940342 AA基因型为参照,各基因多态性位点的其他基因型,均未能显著改变乳腺癌的发病危险(P＞0.05).各基因型风险比分别为1.061(rs249954 TT vs CC),0.793(rs447529 GG vs CC)以及0.921(rs16940342 GG vs AA).结论:PALB2基因rs249954、rs447529及rs16940342多态性可能与福建地区汉族人群早发性乳腺癌的遗传易感性无关,作为低外显率的乳腺癌易感基因位点和未来临床基因筛查的候选指标尚需谨慎.     

乳腺癌中HER-2基因多态性与蛋白表达的相关性研究

背景与目的：致病基因的多态性可能会影响该基因的功能,从而引起个体肿瘤易感性的差异和个体内生物活性物质效应的改变。本研究旨在研究HER-2基因多态性与其蛋白表达的关系,并分析其与乳腺癌临床病理特征的相关性。方法：收集303例汉族女性乳腺癌患者为研究对象,运用MassARRAY技术平台检测HER-2基因rs2517954和rs2517955单核苷酸多态性。同时采用免疫组织化学法检测相应乳腺癌组织中HER-2蛋白表达并检测雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、P53及Ki67表达。以Pearson χ2分析这两个位点和其蛋白表达的关系,并分析其与乳腺癌临床病理特征的相关性。结果：在共显性模型下,HER-2基因rs2517954和rs2517955位点多态性与其蛋白表达相关(χ2=9.613,P=0.008;χ2=9.613,P=0.008)。在显性模型下,HER-2基因rs2517955位点TT纯合突变型和CT杂合突变型的频率与其蛋白表达相关(χ2=8.894,P=0.003)。HER-2基因rs2517954和rs2517955位点多态性与患者的临床分期、肿瘤大小、组织学分级、淋巴结转移、ER、PR、Ki67及P53表达均无显著相关性(P＞0.05)。结论：HER-2基因rs2517955多态性位点与其蛋白表达具有相关性,对该位点进一步研究可能有助于阐明乳腺癌中HER-2蛋白的表达机制。     

TOX3基因单核苷酸多态与中国北方汉族绝经前妇女乳腺癌风险关联的研究

目的:探讨TOX3基因单核苷酸多态与中国北方汉族绝经前妇女乳腺癌风险的关系。方法:采用多重单碱基延伸单核苷酸多态性分型技术(Snapshot)分析方法,检测280例绝经前的乳腺癌患者和287例绝经前的正常对照者TOX3基因rs3803662和rs12443621多态性位点基因型,并比较不同基因型与乳腺癌风险的关系。结果:TOX3基因rs3803662和rs12443621多态性位点基因型频率,在乳腺癌病例组和对照组之间差异无统计学意义,P值分别为0.718和0.340。Logistic回归分析结果显示,对于rs3803662位点,与GG基因型相比,GA、AA和GA+AA基因型与乳腺癌的危险性无关(OR=0.846,95%CI:0.489～1.463,P=0.549;OR=0.802,95%CI:0.470～1.368,P=0.418;OR=0.821,95%CI:0.492～1.368,P=0.449);对于rs12443621位点,与GG基因型相比,GA、AA和GA+AA基因型与乳腺癌的危险性无关(OR=0.755,95%CI:0.518～1.099,P=0.755;OR=0.850,95%CI:0.528～1.368,P=0.504;OR=0.781,95%CI:0.548～1.112,P=0.170)。结论:在目前样本条件下,TOX3基因rs3803662和rs12443621位点多态性与中国北方汉族绝经前妇女乳腺癌易感性之间无明显关联。     

雌激素受体基因ESR1多态性与乳腺癌易感性的关系

目的：研究雌激素受体α（ESR1）基因单核苷酸多态性（SNPs）与乳腺癌易感性的关系。方法：运用聚合酶链反应（PCR）和限制性片段长度多态性（RFLP）分析的方法检测193例中国汉族女性乳腺癌患者和71名正常女性对照者ESR1基因上rs11155816位点的基因型,以SPSS 11.0软件卡方检验处理数据。结果：rs11155816位点等位基因频率符合Hardy-Weinberg遗传平衡定律。rs11155816位点的等位基因及基因型与患者肿瘤位置及是否存在远处转移相关,差异有显著性（P〈0.05）;与年龄、大小、组织学类型、受体表达无关。rs11155816位点等位基因及基因型频率在乳腺癌人群与正常对照者间分布差异有显著性,乳腺癌人群中等位基因A频率高于正常人群（23.8%比15.5%,P〈0.05）。结论：rs11155816位点基因的多态性与乳腺癌患者的肿瘤位置和远处转移相关,等位基因A携带者乳腺癌发病风险较高。     

雌激素受体基因ESR1多态性与乳腺癌易感性的关系

目的:研究雌激素受体α(ESR1)基因单核苷酸多态性(SNPs)与乳腺癌易感性的关系。方法:运用聚合酶链反应(PCR)和限制性片段长度多态性(RFLP)分析的方法检测193例中国汉族女性乳腺癌患者和71名正常女性对照者ESR1基因上rs11155816位点的基因型,以SPSS 11.0软件卡方检验处理数据。结果:rs11155816位点等位基因频率符合Hardy-Weinberg遗传平衡定律。rs11155816位点的等位基因及基因型与患者肿瘤位置及是否存在远处转移相关,差异有显著性(P<0.05);与年龄、大小、组织学类型、受体表达无关。rs11155816位点等位基因及基因型频率在乳腺癌人群与正常对照者间分布差异有显著性,乳腺癌人群中等位基因A频率高于正常人群(23.8%比15.5%,P<0.05)。结论:rs11155816位点基因的多态性与乳腺癌患者的肿瘤位置和远处转移相关,等位基因A携带者乳腺癌发病风险较高。     

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction

The known breast cancer susceptibility polymorphisms in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, and 2q35 confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers. We evaluated the associations of 3 additional single nucleotide polymorphisms (SNPs), rs4973768 in SLC4A7/NEK10, rs6504950 in STXBP4/COX11, and rs10941679 at 5p12, and reanalyzed the previous associations using additional carriers in a sample of 12,525 BRCA1 and 7,409 BRCA2 carriers. Additionally, we investigated potential interactions between SNPs and assessed the implications for risk prediction. The minor alleles of rs4973768 and rs10941679 were associated with increased breast cancer risk for BRCA2 carriers (per-allele HR = 1.10, 95% CI: 1.03-1.18, P = 0.006 and HR = 1.09, 95% CI: 1.01-1.19, P = 0.03, respectively). Neither SNP was associated with breast cancer risk for BRCA1 carriers, and rs6504950 was not associated with breast cancer for either BRCA1 or BRCA2 carriers. Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 × 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively). All risk-associated polymorphisms appear to interact multiplicatively on breast cancer risk for mutation carriers. Based on the joint genotype distribution of the 7 risk-associated SNPs in BRCA2 mutation carriers, the 5% of BRCA2 carriers at highest risk (i.e., between 95th and 100th percentiles) were predicted to have a probability between 80% and 96% of developing breast cancer by age 80, compared with 42% to 50% for the 5% of carriers at lowest risk. Our findings indicated that these risk differences might be sufficient to influence the clinical management of mutation carriers.     

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province

Background

The fibroblast growth factor (FGF) receptor pathway is activated in many tumors. FGFR2 has been identified as a breast cancer susceptibility gene. Common variation in other FGF receptors might also affect breast cancer risk. We carried out a case-control study to investigate associations of variants in FGFR3 and FGFR4 with breast cancer in women from Heilongjiang Province.

Methods

SNP rs2234909 and rs3135848 in FGFR3 and rs1966265 and rs351855 in FGFR4 were successfully genotyped in 747 breast cancer patients and 716 healthy controls using the SNaPshot method. The associations between SNPs and breast cancer were examined by logistic regression. The associations between SNPs and disease characteristics were examined by chi-square tests or one-way ANOVA as needed.

Results

The minor alleles of rs1966265 and rs351855 in FGFR4 were strongly associated with breast cancer in the population, with odds ratios of 1.335 (95%CI = 1.154-1.545) and 1.364 (95%CI = 1.177-1.580), respectively. However, no significant associations were detected between other SNPs and breast cancer. Analyses of the disease characteristics showed that SNP rs351855 was associated with lymph-node-positive breast cancer with a dose-dependent effect of the minor allele (P = 0.008).

Conclusions

SNPs rs1966265 and rs351855 in FGFR4 were associated with breast cancer in a northern Chinese population.     

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Introduction

Previous studies have demonstrated that common breast cancer susceptibility alleles are differentially associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour.

Methods

We used genotype data on up to 11,421 BRCA1 and 7,080 BRCA2 carriers, of whom 4,310 had been affected with breast cancer and had information on either ER or PR status of the tumour, to assess the associations of 12 loci with breast cancer tumour characteristics. Associations were evaluated using a retrospective cohort approach.

Results

The results suggested stronger associations with ER-positive breast cancer than ER-negative for 11 loci in both BRCA1 and BRCA2 carriers. Among BRCA1 carriers, single nucleotide polymorphism (SNP) rs2981582 (FGFR2) exhibited the biggest difference based on ER status (per-allele hazard ratio (HR) for ER-positive = 1.35, 95% CI: 1.17 to 1.56 vs HR = 0.91, 95% CI: 0.85 to 0.98 for ER-negative, P-heterogeneity = 6.5 × 10^-6). In contrast, SNP rs2046210 at 6q25.1 near ESR1 was primarily associated with ER-negative breast cancer risk for both BRCA1 and BRCA2 carriers. In BRCA2 carriers, SNPs in FGFR2, TOX3, LSP1, SLC4A7/NEK10, 5p12, 2q35, and 1p11.2 were significantly associated with ER-positive but not ER-negative disease. Similar results were observed when differentiating breast cancer cases by PR status.

Conclusions

The associations of the 12 SNPs with risk for BRCA1 and BRCA2 carriers differ by ER-positive or ER-negative breast cancer status. The apparent differences in SNP associations between BRCA1 and BRCA2 carriers, and non-carriers, may be explicable by differences in the prevalence of tumour subtypes. As more risk modifying variants are identified, incorporating these associations into breast cancer subtype-specific risk models may improve clinical management for mutation carriers.     

新辅助化疗疗效与乳腺癌Ki67、P53表达的关系

目的探讨新辅助化疗对乳腺癌Ki67、P53表达的影响,以及新的病理评估分级与Ki67、P53的关系。方法 用免疫组织化学染色法分别检测40例Ⅱ～Ⅲ期乳腺癌患者新辅助化疗前后Ki67、P53和其他生物学指标的表达,采用WHO实体肿瘤疗效评价标准和本院病理科制定的病理学分级标准分别对新辅助化疗疗效进行临床综合评估及病理学评价;根据Ki67、P53阳性细胞的百分数分为低表达组和高表达组,分别探讨Ki67、P53不同表达水平与新辅助疗效之间的关系。计数资料采用χ2检验或Fisher精确概率法,等级资料采用非参数秩和检验,相关性分析采用spearman相关。结果 （1）Ki67、P53在乳腺癌组织中的阳性表达率分别为62.5%（25/40）、40.0%（16/40）,高表达率分别为27.5%（11/40）、15.0%（6/40）。Ki67表达与HER-2状态有关（P=0.004）,而与患者年龄、临床分期、ER状态等无关（P〉0.050）;P53表达与一般病理因素均无关（P〉0.050）。（2）Ki67高表达患者新辅助化疗疗效优于低表达的患者（P=0.049）。（3）与新辅助化疗前相比,新辅助化疗后Ki67的阳性表达率显著下降（P=0.027）,但P53的阳性表达率无明显变化（P〉0.050）。（4）经病理学分级评估,Ki67表达的变化程度与新辅助化疗反应有相关性（r=0.347,P=0.028）,但P53的变化程度与新辅助化疗反应无相关性（P〉0.050）。结论 Ki67可作为预测和评估乳腺癌新辅助化疗疗效的生物学指标。     

E R阳性乳腺癌中FGFR1蛋白的表达与ER及预后的关系

背景与目的：乳腺癌是严重危害女性健康的常见恶性肿瘤之一，内分泌治疗是乳腺癌综合治疗中的重要措施之一。约30%激素敏感型乳腺癌患者并不能从内分泌治疗中获益。成纤维细胞生长因子受体1（fibroblast growth factor receptors 1，FGFR1）的表达与雌激素受体（estrogen receptor，ER）阳性乳腺癌患者内分泌治疗耐药可能有关。该研究旨在探讨ER阳性乳腺癌中FGFR1蛋白的表达水平对乳腺癌临床病理学特征及预后的影响。方法：选取哈尔滨医科大学附属肿瘤医院2008年9月-2011年12月收治的184例ER阳性乳腺癌患者，通过免疫组织化学方法检测FGFR1蛋白的表达；采用χ²检验评估FGFR1蛋白水平与乳腺癌临床病理学特征的关系；采用Spearman相关分析评估变量间是否存在相关性；运用COX回归及Kaplan-Meier法分析FGFR1表达水平对乳腺癌预后的影响。结果：在ER阳性乳腺癌中，FGFR1高表达的患者更易发生区域淋巴结转移（P=0.012，r=0.186），且FGFR1的表达水平与ER的表达水平之间存在显著的负相关关系（P=0.011，r=-0.221）。COX单因素分析显示，TNM分期、区域淋巴结转移情况、Ki-67阳性率及FGFR1表达情况与ER阳性乳腺癌预后有关；进一步进行多因素分析发现，淋巴结转移情况（OR=1.744，95%CI：1.002~3.034，P=0.049）和Ki-67阳性率（OR=1.882，95%CI：1.015~3.491，P=0.045）是ER阳性乳腺癌的独立风险因素。Kaplan-Meier生存分析提示，FGFR1高表达患者预后不良（P=0.036）。结论：在ER阳性乳腺癌中，FGFR1蛋白水平与患者ER的表达水平呈显著负相关，且FGFR1高表达提示患者预后不良。     

FGFR4基因多态性与 Luminal 型乳腺癌临床病理特征的相关性

目的：探讨 FGFR4基因多态性与 Luminal 型乳腺癌临床病理指标的关系,为临床个体化治疗提供理论依据。方法：采用多重单碱基延伸（Snapshot）SNP 分型技术,检测415例 Luminal 型乳腺癌患者2个 FGFR4基因多态位点。分析这些多态位点与 Luminal 型乳腺癌临床病理特征的关系。结果：在415例 Luminal 型乳腺癌中,FGFR4基因 rs1966265多态频率分布：纯合野生 AA 型为23．4％、杂合 GA 型为53．7％、纯合突变 GG型为22．9％;rs351855多态频率分布：纯合野生 GG 型为28．2％、杂合 GA 型为53．7％、纯合突变 AA 型为18．1％。两个多态位点与 Luminal 型乳腺癌临床分期、肿瘤大小、组织学分级、淋巴结转移无相关性（P ＞0．05）。结论：FGFR4基因 rs1966265和 rs351855位点多态性与 Luminal 型乳腺癌的临床病理特征之间无明显关联。